Big dreams dominate among next-gen biotech players

Born during a boom but virtually shunned on Wall Street today, this group of upstarts is out to defy some tough odds in birthing a biotech. Here’s John Carroll’s top picks for the next-gen players of 2022 most likely to make their mark — or go down fighting for a landmark change. This marks Carroll’s 20th year selecting top private biotechs for special recognition. Join us at this special event in Boston to recognize this year’s group.

see the winners event recording